about us

Revolutionizing structural heart treatment with innovation.

Coramaze Technologies is a pioneering medtech company advancing Tripair™—a minimally invasive transcatheter solution for tricuspid regurgitation. Tripair aims to redefine structural heart therapy by addressing critical gaps in current treatments, with a solution that is simple, safe and effective.

 

Our vision and purpose

We envision a world where every TR patient, regardless of anatomy, geography and healthcare infrastructure has access to effective treatment. By removing barriers related to anatomical and procedural complexity, cost, and adoption, we intend to ensure that no patient is left untreated. Tripair aims to revolutionize TR treatment with its simplicity, making it safer, more effective, and accessible for physicians worldwide.

Our story

Tripair is being developed with a singular goal: to transform the treatment of tricuspid valve disease with a minimally invasive tricuspid repair technology that leaves no patients behind. With a strong foundation in cardiovascular medicine, biomedical engineering and clinical expertise, we are committed to pushing the boundaries of medical innovation — transforming cutting-edge science into a scalable solution that improves patient outcomes globally.

Coramaze office
Coramaze lab

Investors

MTIP
IV holdings
Seedcapital Dortmund
HGTF

We are supported by renowned international healthcare investors

Become an investor

Led by experts.
Driven by purpose.

Scientific Advisors

Supported by a top-tier network of scientific advisors, we collaborates with leading structural heart experts from around the world to guide the clinical validation of Tripair.

Dr. Paul Sorajja

Director, Center for Valve and Structural Heart, Minneapolis Heart Institute

Dr. Nina Wunderlich

Head of Structural Heart Disease, Asklepios Klinik Langen

Dr. Azeem Latib

Medical Director, Structural Heart Interventions, Montefiore.

Dr. Alison Duncan

Lead Interventional Echocardiographer, Royal Brompton Hospital, London

Dr. Fred St. Goar

Interventional cardiologist at El Camino Health in Mt View

Dr. Federico De Marco

Director, Interventional & Structural Heart Cardiology, Centro Cardiologico Monzino, Italy.

Dr. Erwan Donal

Director, Imaging Lab, University Hospital of Rennes, France.

Dr. Thomas Modine

Cardiovascular and Thoracic Surgeon at Bordeaux University Hospital, Bordeaux France

Dr. Volker Rudolph

Director, Department of General and Interventional Cardiology, Heart and Diabetes Center NRW, Germany.

Management team

Led by experts in medtech and structural heart care, our management team combines clinical insight with industry know-how to advance innovation and bring Tripair to patients around the world.

Jochen Reinöhl

CEO

Neil Moat

Chief Medical Officer

Mary Edwards

Regulatory

Grayston Licht

CTO

Laurie Hayner

VP Clinical Operations

Shai Assia

VP R&D

Jacob van Dam

Director of Quality Assurance

Carmel van den Berk

Chief of Staff

Konstantin Winterhalder

Director Finance

Board members

Tripair is guided by a strategic and experienced Board of Directors, benefitting from deep industry insight and global leadership to drive its mission forward.

Rob ten Hoedt

Chairman of the Board

Christoph Kausch

Board Director

Erich Platzer

Board Director

Claude Herskovits

Board Director

Be at the forefront of MedTech.

Careers
Join us

Join a team that's shaping the future of structural heart care. At Coramaze, you'll work alongside leading experts to bring Tripair™—our breakthrough solution for tricuspid regurgitation—to patients worldwide. Ready to make a real impact? Join us in building the future of cardiovascular innovation.

Join us in pioneering the future of tricuspid regurgitation treatment.